Sign up
Pharma Capital

Rep Boost for Futura Medical's Erectile Dysfunction gel

Sexual intimacy cures have been pedalled for centuries but science is now in the marketplace with, among others,  Futura Medical's (LON:FUM) MED2002 gel getting noticed in all the right places.The publication, The Journal of Sexual Medicine, is a bit late to the party given that the headline results were announced back in September 2016 but Futura said it nonetheless shows the growing “level of scientific interest” in the gel. CEO James Barder tells Proactive why he thinks MED2002 is superior to the two other main orally-taken competitors. James also updates us on the company's Clinical Development programme and progressing their Phase III pathway through 2018.


View full FUM profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.